week 64 check-in — 25kg down, early fullness manageable, one thing confusing me
week 64 check-in — 25kg down, early fullness manageable, one thing confusing me. Same spreadsheet I have been keeping since the start, nothing retrofitted.
To save the first four comments: week 64 and 25kg.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Corrected a cross-class dose comparison in the title. The body is untouched.
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
Went looking for independent testing on this and found essentially nothing, which was clarifying.
daily dosing, not weekly, so the exposure profile is different
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.